SGMO
SANGAMO THERAPEUTICS, INCCompany Information
- Company Name
- SANGAMO THERAPEUTICS, INC
- CIK
- CIK0001001233
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SGMO: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SGMO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-04-22
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 415,769
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 509,379
- Shares outstanding
- 389,616,000
- Ownership
- 0.13%
Earnings Market Reaction
- Filing date
- 2026-05-14
- Price on filing date
- —
- 1-month reaction
- 57.14%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 28 | 21 | 30 | 38 | 25 | 42 | 39 | 28 | 54 | 45 | 57 | 67 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | - | 76 | ||||||
| Restricted Cash Current | - | - | 1 | - | - | - | 0 | - | 1 | - | - | - | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 36 | 76 | - | ||||||
| Accounts Receivable Net Current | 1 | 0 | 1 | 0 | 0 | 1 | 10 | 1 | 1 | 1 | 1 | 3 | ||||||
| Interest Receivable Current | - | - | - | - | - | - | - | - | - | 0 | 1 | 1 | ||||||
| Income Taxes Receivable | 5 | 10 | 5 | 5 | 4 | 4 | - | - | - | 3 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 8 | 7 | 8 | 5 | 8 | 12 | 13 | 9 | 14 | 13 | ||||||
| Assets Current | 37 | 36 | 44 | 50 | 38 | 52 | 58 | 40 | 69 | 94 | 148 | 160 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 39 | ||||||
| Property Plant And Equipment Net | 10 | 11 | 15 | 16 | 17 | 18 | 19 | 21 | 22 | 27 | 28 | 61 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 14 | 15 | 16 | 17 | 18 | 19 | 21 | 26 | 27 | 47 | ||||||
| Income Taxes Receivable Noncurrent | 9 | 9 | 14 | 14 | 13 | 13 | - | - | - | 15 | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | 1 | 15 | 17 | ||||||
| Goodwill | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | - | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | ||||||
| Assets | 60 | 60 | 89 | 98 | 86 | 102 | 111 | 93 | 129 | 165 | 220 | 325 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 19 | 14 | 16 | 11 | 18 | 15 | 20 | 18 | 15 | 15 | 15 | 15 | ||||||
| Accrued Employee Benefits Current | 18 | 18 | 17 | 15 | 14 | 15 | 11 | 6 | 6 | 9 | 17 | 13 | ||||||
| Accrued Liabilities Current | 15 | 9 | 10 | 14 | 10 | 8 | 12 | 16 | 18 | 24 | 14 | 19 | ||||||
| Contract With Customer Liability Current | 0 | 1 | 8 | 8 | 8 | 8 | 1 | - | - | 0 | 1 | 7 | ||||||
| Liabilities Current | 53 | 42 | 50 | 48 | 50 | 46 | 43 | 39 | 40 | 48 | 48 | 54 | ||||||
| Contract With Customer Liability Noncurrent | 6 | 6 | 6 | 6 | 6 | 6 | - | - | - | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 19 | 25 | 25 | 23 | 25 | 26 | 28 | 29 | 31 | 34 | 35 | 36 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | 0 | - | - | - | - | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 79 | 74 | 82 | 78 | 81 | 79 | 72 | 69 | 72 | 82 | 85 | 91 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 4 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Additional Paid In Capital Common Stock | 1,638 | 1,611 | 1,594 | 1,573 | 1,543 | 1,532 | 1,522 | 1,519 | 1,516 | 1,492 | 1,486 | 1,480 | ||||||
| Retained Earnings Accumulated Deficit | -1,658 | -1,627 | -1,590 | -1,555 | -1,535 | -1,504 | -1,481 | -1,492 | -1,455 | -1,406 | -1,346 | -1,242 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -1 | -1 | -1 | -6 | -8 | -4 | -6 | -6 | -5 | -7 | -6 | ||||||
| Stockholders Equity | -19 | -14 | 6 | 20 | 5 | 23 | 39 | 24 | 57 | 83 | 135 | 234 | ||||||
| Liabilities And Stockholders Equity | 60 | 60 | 89 | 98 | 86 | 102 | 111 | 93 | 129 | 165 | 220 | 325 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | 0.01 | - | - | - | 0.01 | - | - | - | 0.01 | - | - | ||||||
| Preferred Stock Shares Authorized | - | 5 | - | - | - | 5 | - | - | - | 5 | - | - | ||||||
| Preferred Stock Shares Issued | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | ||||||
| Preferred Stock Shares Outstanding | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | 0.01 | - | - | - | 0.01 | - | - | - | 0.01 | - | - | ||||||
| Common Stock Shares Authorized | - | 960 | - | - | - | 960 | - | - | - | 960 | - | - | ||||||
| Common Stock Shares Issued | - | 351 | - | - | - | 213 | - | - | - | 178 | - | - | ||||||
| Shares Outstanding | - | 351 | - | - | - | 213 | - | - | - | 178 | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSANGAMO THERAPEUTICS, INC (SGMO) — SEC Financial Statements & Analysis
SANGAMO THERAPEUTICS, INC (SGMO) is a biological products, (no diagnostic substances) company, incorporated in DE. SANGAMO THERAPEUTICS, INC trades on OTC as: SGMO. SANGAMO THERAPEUTICS, INC (SGMO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14. Based on that filing, On profitability, SANGAMO THERAPEUTICS, INC posts an operating margin of -357.55%, a net margin of -356.89%, a Return on Equity (ROE) of 1755.71%, a Return on Assets (ROA) of -168.79%, and a Return on Invested Capital (ROIC) of -257.77%. Per share, it reports EPS of $-0.32, diluted EPS of $-0.32, free cash flow per share of $-0.23, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -45.80% year-over-year, net income growth of 55.23% year-over-year, and EPS growth of -12.24% year-over-year. On the balance sheet, it maintains a current ratio of 0.70x, a quick ratio of 0.64x, working capital of $-16.02M, a debt-to-equity ratio of -4.16x, a debt ratio of 1.32, free cash flow of $-90.46M (TTM), and net debt of $-27.59M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.32
- ROE TTM
- 1755.71%
- ROA TTM
- -168.79%
- Debt To Equity
- -4.16x
- Free Cash Flow TTM
- $-90.46M
- Net Revenue TTM Growth 1Y
- -45.80%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SANGAMO THERAPEUTICS, INC in?
SANGAMO THERAPEUTICS, INC (SGMO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SGMO trade on?
SANGAMO THERAPEUTICS, INC (SGMO) trades on the OTC.
Where is SANGAMO THERAPEUTICS, INC incorporated?
SANGAMO THERAPEUTICS, INC is incorporated in DE.
When was SANGAMO THERAPEUTICS, INC (SGMO)'s most recent SEC filing?
SANGAMO THERAPEUTICS, INC (SGMO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-14.
What is SGMO's EPS (earnings per share)?
SANGAMO THERAPEUTICS, INC (SGMO)'s trailing twelve month EPS is $-0.32 as of 2026-03-31.
What is SGMO's ROE (return on equity)?
SANGAMO THERAPEUTICS, INC (SGMO)'s trailing twelve month Return on Equity (ROE) is 1755.71% as of 2026-03-31.
What is SGMO's ROA (return on assets)?
SANGAMO THERAPEUTICS, INC (SGMO)'s trailing twelve month Return on Assets (ROA) is -168.79% as of 2026-03-31.
What is SGMO's ROIC (return on invested capital)?
SANGAMO THERAPEUTICS, INC (SGMO)'s trailing twelve month Return on Invested Capital (ROIC) is -257.77% as of 2024-03-31.